Watson In Patent Dispute Over Teva's Azilect

From Associated Press (October 5, 2010)


NEW YORK -- Watson Pharmaceuticals Inc. said Tuesday it is being sued by Teva Pharmaceuticals Ltd. over plans to make a generic version of the Parkinson’s drug Azilect.

Watson asked the Food and Drug Administration to approve a generic version of the Teva drug, prompting the lawsuit by Teva for patent infringement in the U.S. District Court for the District of New Jersey. The lawsuit puts approval of the generic version on hold until Nov. 16, 2013 or earlier, depending on the final decision by the court.

Watson said Azilect had sales of $108 million for the 12 months ended June 30, citing IMS Health data.

 

Posted: October 2010


View comments

Hide
(web1)